Nanologica (NICA) Q3 2025 earnings summary

Executive summary

• Net sales for Q3 2025 reached SEK 2,843 thousand, up from SEK 611 thousand year-over-year; nine-month sales totaled SEK 15,930 thousand, nearly doubling from SEK 7,822 thousand.

• Operating loss for Q3 was SEK -10,017 thousand, a significant improvement from SEK -22,203 thousand in Q3 2024; nine-month operating loss was SEK -30,021 thousand, also improved from SEK -47,365 thousand.

• Stable production was achieved during the quarter, enabling the company to fulfill its first order for the insulin market and launch a new product, NLAB Idun.

• Cash and cash equivalents as of September 30, 2025, were SEK 13,970 thousand, up from SEK 4,087 thousand a year earlier.

Financial highlights

• Net sales for Q3 2025: SEK 2,843 thousand (Q3 2024: SEK 611 thousand); nine months: SEK 15,930 thousand (2024: SEK 7,822 thousand).

• Operating loss for Q3 2025: SEK -10,017 thousand (Q3 2024: SEK -22,203 thousand); nine months: SEK -30,021 thousand (2024: SEK -47,365 thousand).

• Loss before tax for Q3 2025: SEK -10,998 thousand (Q3 2024: SEK -23,701 thousand); nine months: SEK -33,481 thousand (2024: SEK -51,561 thousand).

• Earnings per share (basic and diluted) for Q3 2025: SEK -0.12 (Q3 2024: SEK -0.54); nine months: SEK -0.38 (2024: SEK -1.24).

• Cash flow from operating activities for Q3 2025: SEK -10,682 thousand (Q3 2024: SEK -23,474 thousand).

Outlook and guidance

• Large-scale silica production is now delivering higher volumes, expected to facilitate commercialization and enable larger sales with continued growth in coming years.

• Order intake for Q4 already amounts to approximately SEK 5.7 million, indicating a positive sales trend.